This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,

Jumeirah Lakes Towers, Dubai,

United Arab Emirates

Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Parkinson's Disease Therapeutics Market

Market Insights on Parkinson's Disease Therapeutics covering sales outlook, demand forecast & up-to-date key trends

Parkinson's Disease Therapeutics Market by Drug Class, Route of Administration, Distribution Channel & Region | Forecast 2022 to 2032

Parkinson’s Disease Drug Therapeutics Market Overview (2022 to 2032)

The global Parkinson’s disease drug therapeutics market was valued at around US$ 4.5 Billion at the end of 2021. The market is projected to register an 8.4% CAGR and top a valuation of US$ 10.9 Billion by 2032.

A rapidly growing geriatric population, promising pipeline drugs, and new product launches are expected to uplift the Parkinson’s disease drug therapeutics market growth.

Parkinson's disease damages the brain's dopamine-producing nerve cells and is a neurodegenerative disorder. Tremors, muscle rigidity, incorrect motor movements, and issues with walking and balance are the main symptoms of Parkinson's disease. Anxiety, depression, and dementia are additional signs and symptoms of Parkinson's disease.

Certain brain nerve cells (neurons) eventually deteriorate or die in Parkinson's disease. A decrease in neurons that produce the chemical messenger dopamine in your brain is the cause of many symptoms. Dopamine deficiency results in abnormal brain activity, which worsens movement impairment and other Parkinson's disease symptoms.

Attributes

Details

Parkinson’s Disease Drug Therapeutics Market Value in 2021

US$ 4.5 Billion

Parkinson’s Disease Drug Therapeutics Market Value in 2032

US$ 10.9 Billion

Parkinson’s Disease Drug Therapeutics Market CAGR (2022 to 2032)

8.4%

Customize this Report

Let us know your requirement to get
100% FREE customization

What are the Major Drivers Boosting the Demand for Parkinson’s Disease Drug Therapeutics Market?

Major market drivers are projected to be the increase in demand for Parkinson’s Disease drugs, the growing geriatric population, who are at a greater risk of acquiring Parkinson's Disease (PD), the high prevalence of PD in western nations, and the robust product pipeline of disease-modifying treatments.

The global Parkinson's disease drug therapeutics market also points to an increase in male patients, since men have a 1.5 times higher risk of developing the illness than women, according to statistics from the Parkinson's disease establishment.

The rise in clinical Research and Development spending by governments and non-profit organizations, together with growing public awareness of Parkinson's disease, is anticipated to drive the market for Parkinson's disease drug therapeutics over the forecast period. During the projected period, the attractive product pipeline will represent potential business development opportunities.

Which Region Shows Strong Growth Potential in the Parkinson’s Disease Drug Therapeutics Market?

In comparison to other regions, North America has the greatest market for Parkinson’s disease drug therapeutics sales and makes the most contribution. Due to the availability of well-established diagnostic laboratories, the presence of key players, and the high number of skilled neurologists.

The major share of Europe has been largely attributed to patients' high level of awareness, advantageous medical reimbursement systems, high prevalence of Parkinson's disease, and promising clinical pipeline products. Due to the increased product penetration, untapped potential, and growing prevalence of PD coupled with growing numbers of elderly individuals in developing countries like China, India is forecasting strong development for the respiratory monitoring devices market.

Sabyasachi Ghosh
Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Who are the Key Players in the Parkinson’s Disease Drug Therapeutics Market?

Cerevel Therapeutics, Novartis AG, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., GlaxoSmithKline plc. (GSK), AbbVie, Inc., H. Lundbeck A/S, Amneal Pharmaceuticals LLC, Supernus Pharmaceuticals, Inc., Sun Pharmaceuticals Ltd., Cipla, Pfizer Inc., GlaxoSmithKline Plc.

Scope of Report

Report Attributes

Details

Growth Rate

CAGR of 8.4% from 2022 to 2032

Base Year for Estimation

2021

Historical Data

2012 to 2021

Forecast Period

2022 to 2032

Qualitative Units

Revenue in USD Billion, and CAGR from 2022 to 2032

Report Coverage

Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends

Segment Covered

  • Drug Class
  • Route of Administration
  • Distribution Channel
  • Region

Region Covered

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa

Key Countries Profiled

  • USA
  • Canada
  • Brazil
  • Mexico
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • China
  • Japan
  • South Korea
  • Malaysia
  • Singapore
  • Australia
  • New Zealand
  • GCC Countries
  • South Africa
  • Israel

Key Players

  • Cerevel Therapeutics
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.
  • GlaxoSmithKline plc. (GSK)
  • AbbVie, Inc.
  • H. Lundbeck A/S
  • Amneal Pharmaceuticals LLC
  • Supernus Pharmaceuticals, Inc.
  • Sun Pharmaceuticals Ltd.
  • Cipla
  • Pfizer Inc.
  • GlaxoSmithKline Plc.

Customization

Available Upon Request

MarketNage
Become a MarketNgage Insider

A unified Market Research Subscription Platform, built for today's disparate research needs.

Key Segments Covered in the Parkinson’s Disease Drug Therapeutics Industry Survey

By Drug Class:

  • Levodopa Combination
  • Dopamine Agonists
  • MAO-B Inhibitors
  • COMT Inhibitors
  • Others

By Route of Administration:

  • Oral
  • Injectable
  • Nasal
  • Transdermal
  • Others

By Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East and Africa

Frequently Asked Questions

The global Parkinson’s disease drug therapeutics market is anticipated to register a CAGR of 8.4% during the forecast period.

The top players in the global Parkinson’s disease drug therapeutics market are Cerevel Therapeutics, Novartis AG, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., GlaxoSmithKline plc. (GSK), AbbVie, Inc., H. Lundbeck A/S, Amneal Pharmaceuticals LLC, Supernus Pharmaceuticals, Inc., Sun Pharmaceuticals Ltd., Cipla, Pfizer Inc., GlaxoSmithKline Plc.

Table of Content

NA
Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

NA
Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

NA

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Asthma and COPD Biomarkers Market

Published : June 2018

Healthcare

COPD Therapeutics Market

Published : July 2017

Healthcare

Microbiome Therapeutics Market

Published : January 2017

Healthcare

Equine Veterinary Therapeutics Market

Published : December 2016

Google translate

Parkinson's Disease Therapeutics Market